Your blogger

My photo
When Roger West first launched the progressive political blog "News From The Other Side" in May 2010, he could hardly have predicted the impact that his venture would have on the media and political debate. As the New Media emerged as a counterbalance to established media sources, Roger wrote his copious blogs about national politics, the tea party movement, mid-term elections, and the failings of the radical right to the vanguard of the New Media movement. Roger West's efforts as a leading blogger have tremendous reach. NFTOS has led the effort to bring accountability to mainstream media sources such as FOX NEWS,CNN and Andy Breitbart's "Big Journalism. Roger's breadth of experience, engaging style, and cultivation of loyal readership - over 92 million visitors - give him unique insight into the past, present, and future of the New Media and political rhetoric that exists in our society today. What we are against: Radical Right Wing Agendas Incompetent Establishment Public Coruption Corporate Malfeasence We are for: Global and Econmoic Security Social and Economic Justice Media Accountability Healthy Communities

Saturday, October 24, 2015

PHARMA BRO GETS BESTED

A San Diego-based company announced on Thursday that it would compete with Martin Shkreli’s Turing Pharmaceuticals by offering the same drug used to help AIDS and cancer patients for $1 a pill, the San Diego Union-Tribune reported.

Imprimis Pharmaceuticals, a compounding-drug firm, said it would begin selling its own version of the generic drug pyrimethamine, which Turing was marketing under the name Daraprim. Shkreli was roundly criticized last month after his company raised the price for the drug from $13.50 a pill to $750 a pill after acquiring the patent.

The version Imprimis will be selling includes pyrimethamine and another generic drug, leucovorin, which is typically used to help cancer patients going through chemotherapy. The two drugs are the active ingredients in Daraprim.

Mark Baum, Imprimis’ CEO, said his company plans to offer similar compounded drugs soon.

“We are looking at all of these cases where the sole-source generic companies are jacking the price way up,” he told the Associated Press. “There’ll be many more of these.”
According to Baum, his company’s mix of the two drugs has not been approved by the Food and Drug Administration. However, both the ingredients themselves and the company’s compounding work have been approved. The drug can only be sold after being prescribed by a doctor to a specific individual.

The company is selling a bottle of 100 pills for $99 through its website.





NFTOS
STAFF WRITER